Jump to content

Ketamine-assisted psychotherapy: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Citation bot (talk | contribs)
Bots
4,958,586 edits
Alter: title, url. URLs might have been anonymized. Add: pmid, s2cid, doi-access, authors 1-1. Removed proxy/dead URL that duplicated identifier. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by AManWithNoPlan | #UCB_CommandLine
I reformatted a lot of the content to make it more coherent. I also added more content to the overview and background, its effects on treatment-resistant depression, and the limitations and future directions of KAP research.
Line 2: Line 2:
{{Psychology sidebar}}
{{Psychology sidebar}}


'''Ketamine-assisted psychotherapy''' '''(KAP)''', is the use of prescribed doses of [[ketamine]], the drug, as an adjunct to [[psychotherapy]] sessions. KAP shows significant potential in treating [[Mental disorder|mental disorders]] such as [[treatment-resistant depression]] (TRD), [[Anxiety disorder|anxiety]], [[Obsessive–compulsive disorder|obsessive-compulsive disorders]] (OCD), and [[Post-traumatic stress disorder|post-traumatic stress disorders]] (PTSD). It can also be used for those experiencing [[substance abuse]] and [[physical pain]]. While it is primarily used as a veterinary [[Anesthetic|anaesthetic]], ketamine has also been found to have rapid [[analgesic]] and [[Hallucinogen|hallucinogenic]] effects<ref name=":03">{{Cite journal |last=Drozdz |first=Sandra J |last2=Goel |first2=Akash |last3=McGarr |first3=Matthew W |last4=Katz |first4=Joel |last5=Ritvo |first5=Paul |last6=Mattina |first6=Gabriella F |last7=Bhat |first7=Venkat |last8=Diep |first8=Calvin |last9=Ladha |first9=Karim S |date=2022-12-31 |title=Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature |url=https://www.tandfonline.com/doi/abs/10.2147/JPR.S360733 |journal=Journal of Pain Research |volume=15 |pages=1691–1706 |doi=10.2147/JPR.S360733 |pmc=PMC9207256 |pmid=35734507}}</ref><ref>{{Cite journal |last=Nowacka |first=Agata |last2=Borczyk |first2=Malgorzata |date=2019-10-05 |title=Ketamine applications beyond anesthesia – A literature review |url=https://www.sciencedirect.com/science/article/pii/S0014299919304996 |journal=European Journal of Pharmacology |language=en |volume=860 |pages=172547 |doi=10.1016/j.ejphar.2019.172547 |issn=0014-2999}}</ref>, which has sparked interest in its use as an [[antidepressant]]. Despite initial trials of its use in the treatment of mental disorders focussing primarily on its antidepressant effects, newer studies are attempting to harness its [[Psychedelic drug|psychedelic]] effects to bring about altered states of consciousness, which will augment the adjunct psychotherapy. Ketamine’s [[neuroplasticity]]-promoting effects strengthen the cognitive restructuring that takes place through traditional psychotherapy, thereby leading to long-lasting behavioural change<ref>{{Cite journal |last=Krystal |first=John H. |date=2007-10-15 |title=Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy |url=https://www.biologicalpsychiatryjournal.com/article/S0006-3223(07)00825-6/fulltext |journal=Biological Psychiatry |language=English |volume=62 |issue=8 |pages=833–834 |doi=10.1016/j.biopsych.2007.08.017 |issn=0006-3223}}</ref><ref>{{Cite journal |last=Greenway |first=Kyle T. |last2=Garel |first2=Nicolas |last3=Jerome |first3=Lisa |last4=Feduccia |first4=Allison A. |date=2020-06-02 |title=Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments |url=https://doi.org/10.1080/17512433.2020.1772054 |journal=Expert Review of Clinical Pharmacology |volume=13 |issue=6 |pages=655–670 |doi=10.1080/17512433.2020.1772054 |issn=1751-2433 |pmid=32478631}}</ref>. KAP offers promising directions for research on new antidepressant alternatives, but is still not sufficiently defined or evaluated as a treatment combination.
'''Ketamine-assisted psychotherapy''', sometimes abbreviated as '''KAP''', is the use of prescribed doses of [[ketamine]] as an adjunct to [[psychotherapy]] sessions. Ketamine-assisted psychotherapy can be used to treat [[Mental disorder|mental health issues]], such as treatment resistant depression (TRD), anxiety, and PTSD. It can also be used for those experiencing [[substance abuse]] and [[physical pain]]. One of the significant benefits of ketamine-based therapy is that compared to other [[antidepressant]]s, which have a very slow onset time, ketamine is very rapidly acting [[analgesic]].<ref name=":0" /> Ketamine-assisted psychotherapy is a specific therapy that combines ketamine with traditional talk therapy to augment the effects of both. 


== Background ==
== Background ==
Ketamine is a short-acting, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist.<ref name=":0">{{Cite journal |last1=Drozdz |first1=Sandra J |last2=Goel |first2=Akash |last3=McGarr |first3=Matthew W |last4=Katz |first4=Joel |last5=Ritvo |first5=Paul |last6=Mattina |first6=Gabriella F |last7=Bhat |first7=Venkat |last8=Diep |first8=Calvin |last9=Ladha |first9=Karim S |date=2022-06-15 |title=Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature |journal=Journal of Pain Research |volume=15 |pages=1691–1706 |doi=10.2147/JPR.S360733 |issn=1178-7090 |pmc=9207256 |pmid=35734507}}</ref> It was discovered by Parke-Davis Labs and Dr. Calvin Lee Stevens in 1962 during research into derivatives of phencyclidine (PCP).<ref name=":1">{{Cite journal |last1=Mathai |first1=David S. |last2=Mora |first2=Victoria |last3=Garcia-Romeu |first3=Albert |date=2022-03-25 |title=Toward Synergies of Ketamine and Psychotherapy |journal=Frontiers in Psychology |volume=13 |pages=868103 |doi=10.3389/fpsyg.2022.868103 |issn=1664-1078 |pmc=8992793 |pmid=35401323|doi-access=free }}</ref> It was first used clinically as an [[anesthetic]]. Given its hallucinogenic properties, interest rapidly rose in the possibility of broader avenues of application, including within the field of psychiatry as a treatment for depression, substance use dependence, and more.<ref>{{Cite journal |last1=Dore |first1=Jennifer |last2=Turnipseed |first2=Brent |last3=Dwyer |first3=Shannon |last4=Turnipseed |first4=Andrea |last5=Andries |first5=Julane |last6=Ascani |first6=German |last7=Monnette |first7=Celeste |last8=Huidekoper |first8=Angela |last9=Strauss |first9=Nicole |last10=Wolfson |first10=Phil |date=2019-03-15 |title=Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy |url=https://doi.org/10.1080/02791072.2019.1587556 |journal=Journal of Psychoactive Drugs |volume=51 |issue=2 |pages=189–198 |doi=10.1080/02791072.2019.1587556 |issn=0279-1072 |pmid=30917760|s2cid=85543704 }}</ref> Because symptom reduction usually only lasts 4 to 7 days, investigation into ketamine as an adjunct to psychotherapy in order for patients to gain long-term benefits has been a topic of interest.<ref name=":0" /> The combination of pharmacotherapy and psychotherapy has historically been efficacious in numerous instances, such as the pairing of psychotherapy with conventional antidepressants for mood and anxiety disorders, with [[naltrexone]] for alcohol and opioid dependence, and with [[bupropion]] for smoking cessation.<ref name=":1" />
Ketamine is a short-acting, noncompetitive [[N-Methyl-D-aspartic acid|N-methyl-D-aspartate]] (NMDA) receptor antagonist<ref name=":03" />. It was discovered by Parke-Davis Labs and Dr. Calvin Lee Stevens in 1962 during research into derivatives of [[phencyclidine]] (PCP).<ref name=":13">{{Cite journal |last=Mathai |first=David S. |last2=Mora |first2=Victoria |last3=Garcia-Romeu |first3=Albert |date=2022 |title=Toward Synergies of Ketamine and Psychotherapy |url=https://www.frontiersin.org/articles/10.3389/fpsyg.2022.868103 |journal=Frontiers in Psychology |volume=13 |doi=10.3389/fpsyg.2022.868103 |issn=1664-1078 |pmc=PMC8992793 |pmid=35401323}}</ref> It was first used clinically as a veterinary [[Anesthetic|anaesthetic]]. Given its hallucinogenic properties, interest rapidly rose in the possibility of broader avenues of application, including within the field of psychiatry as a treatment for depression, substance use dependence, and more.<ref name=":23">{{Cite journal |last=Dore |first=Jennifer |last2=Turnipseed |first2=Brent |last3=Dwyer |first3=Shannon |last4=Turnipseed |first4=Andrea |last5=Andries |first5=Julane |last6=Ascani |first6=German |last7=Monnette |first7=Celeste |last8=Huidekoper |first8=Angela |last9=Strauss |first9=Nicole |last10=Wolfson |first10=Phil |date=2019-03-15 |title=Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy |url=https://doi.org/10.1080/02791072.2019.1587556 |journal=Journal of Psychoactive Drugs |volume=51 |issue=2 |pages=189–198 |doi=10.1080/02791072.2019.1587556 |issn=0279-1072 |pmid=30917760}}</ref> The USA [[Food and Drug Administration]] (FDA) first approved the use of intranasal [[esketamine]] ([[Esketamine|Spravato]])—an [[enantiomer]] of ketamine—for the use of ketamine-derived therapy for treatment-resistant depression, in 2019.<ref name=":0">{{Cite journal |last=Research |first=Center for Drug Evaluation and |date=2022-02-16 |title=FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray |url=https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray |journal=FDA |language=en}}</ref> Ketamine is currently one of the two injected general anaesthetics that the [[World Health Organization|World Health Organisation]] includes in its Model List of Essential Medicines.

=== Rationale behind ketamine-assisted psychotherapy ===
Current antidepressant treatment is heavily limited by its delayed onset of efficacy, with noticeable effects only appearing over a period of months. The Sequenced Treatment Alternatives to Relieve Depression Study (STAR*D) Trial<ref>{{Cite journal |last=Sinyor |first=Mark |last2=Schaffer |first2=Ayal |last3=Levitt |first3=Anthony |date=2010-03 |title=The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review |url=http://journals.sagepub.com/doi/10.1177/070674371005500303 |journal=The Canadian Journal of Psychiatry |language=en |volume=55 |issue=3 |pages=126–135 |doi=10.1177/070674371005500303 |issn=0706-7437}}</ref> also found that patients had low response rates to alternative compounds after the failure of the first antidepressant.<ref name=":03" /><ref>{{Cite journal |last=Naughton |first=Marie |last2=Clarke |first2=Gerard |last3=O′Leary |first3=Olivia F. |last4=Cryan |first4=John F. |last5=Dinan |first5=Timothy G. |date=2014-03-01 |title=A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action |url=https://www.sciencedirect.com/science/article/pii/S0165032713008252 |journal=Journal of Affective Disorders |language=en |volume=156 |pages=24–35 |doi=10.1016/j.jad.2013.11.014 |issn=0165-0327}}</ref> Thus, a need for more rapid, yet prolonged, efficacy in treatment has stimulated further research on alternative treatment options.

Research evidence has found that the integrated use of psychotherapy and antidepressant medication to treat mental disorders, enhances the effects of both<ref name=":03" /><ref name=":23" /><ref name=":32">{{Cite journal |last=Walsh |first=Zach |last2=Mollaahmetoglu |first2=Ozden Merve |last3=Rootman |first3=Joseph |last4=Golsof |first4=Shannon |last5=Keeler |first5=Johanna |last6=Marsh |first6=Beth |last7=Nutt |first7=David J. |last8=Morgan |first8=Celia J. A. |date=2022-01 |title=Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review |url=https://www.cambridge.org/core/journals/bjpsych-open/article/ketamine-for-the-treatment-of-mental-health-and-substance-use-disorders-comprehensive-systematic-review/36E261BFA62CDA6459B88F7777415FDA |journal=BJPsych Open |language=en |volume=8 |issue=1 |pages=e19 |doi=10.1192/bjo.2021.1061 |issn=2056-4724}}</ref>. The combination of pharmacotherapy and psychotherapy has historically been efficacious in numerous instances, such as the pairing of psychotherapy with conventional antidepressants for mood and anxiety disorders, with [[naltrexone]] for alcohol and opioid dependence, and with [[bupropion]] for smoking cessation.<ref name=":13" /> Ketamine offers a notable advantage as opposed to currently-approved antidepressants, as it has a rapid onset<ref name=":42">{{Cite journal |last=Hasler |first=Gregor |date=2020-06 |title=Toward specific ways to combine ketamine and psychotherapy in treating depression |url=https://www.cambridge.org/core/journals/cns-spectrums/article/toward-specific-ways-to-combine-ketamine-and-psychotherapy-in-treating-depression/E9A21495A721D7838DC76AAD8BDC87BA |journal=CNS Spectrums |language=en |volume=25 |issue=3 |pages=445–447 |doi=10.1017/S1092852919001007 |issn=1092-8529}}</ref> (2-24 hours post-infusion)<ref>{{Cite journal |last=Singh |first=Jaskaran B. |last2=Fedgchin |first2=Maggie |last3=Daly |first3=Ella J. |last4=De Boer |first4=Peter |last5=Cooper |first5=Kimberly |last6=Lim |first6=Pilar |last7=Pinter |first7=Christine |last8=Murrough |first8=James W. |last9=Sanacora |first9=Gerard |last10=Shelton |first10=Richard C. |last11=Kurian |first11=Benji |last12=Winokur |first12=Andrew |last13=Fava |first13=Maurizio |last14=Manji |first14=Husseini |last15=Drevets |first15=Wayne C. |date=2016-08 |title=A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression |url=http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2016.16010037 |journal=American Journal of Psychiatry |language=en |volume=173 |issue=8 |pages=816–826 |doi=10.1176/appi.ajp.2016.16010037 |issn=0002-953X}}</ref> of temporally limited, but sustained, antidepressant and analgesic effects (typically lasting 4-7 days).<ref name=":03" /> Its dissociative, psychedelic effects could also provide patients with increased neuroplasticity and cognitive flexibility that would enable more effective participation in therapy sessions.<ref name=":42" /> Therapy could, in turn, reinforce the effects and improvements facilitated by ketamine to provide longer-lasting treatment<ref name=":42" /><ref>{{Cite journal |last=Doblin |first=Richard E. |last2=Christiansen |first2=Merete |last3=Jerome |first3=Lisa |last4=Burge |first4=Brad |date=2019-03-15 |title=The Past and Future of Psychedelic Science: An Introduction to This Issue |url=https://doi.org/10.1080/02791072.2019.1606472 |journal=Journal of Psychoactive Drugs |volume=51 |issue=2 |pages=93–97 |doi=10.1080/02791072.2019.1606472 |issn=0279-1072 |pmid=31132970}}</ref>. Supplementing ketamine use with [[Cognitive behavioral therapy|cognitive behaviour therapy]] (CBT), in particular, has the potential to help patients reverse their inaccurate beliefs and maladaptive processing of information, that lead to depressive mental states.<ref>{{Cite journal |last=Joneborg |first=Isak |last2=Lee |first2=Yena |last3=Di Vincenzo |first3=Joshua D. |last4=Ceban |first4=Felicia |last5=Meshkat |first5=Shakila |last6=Lui |first6=Leanna M. W. |last7=Fancy |first7=Farhan |last8=Rosenblat |first8=Joshua D. |last9=McIntyre |first9=Roger S. |date=2022-10-15 |title=Active mechanisms of ketamine-assisted psychotherapy: A systematic review |url=https://www.sciencedirect.com/science/article/pii/S0165032722007984 |journal=Journal of Affective Disorders |language=en |volume=315 |pages=105–112 |doi=10.1016/j.jad.2022.07.030 |issn=0165-0327}}</ref>


== Active mechanisms ==
== Active mechanisms ==
There are several hypotheses as to the underlying neural and cognitive mechanisms responsible for the psychiatric effects of ketamine.<ref name=":0" /> Its mechanism of action is as an NMDA receptor antagonist. As such, [[Glutamic acid|glutamate]] modulation is a well-known effect, which is specifically believed to confer increased synaptic excitability. Notably, however, the effects of ketamine are now believed to be larger in scope than previously thought, ultimately leading to greater synaptogenesis and [[neuroplasticity]].<ref name=":2">{{Cite journal |last1=Joneborg |first1=Isak |last2=Lee |first2=Yena |last3=Di Vincenzo |first3=Joshua D. |last4=Ceban |first4=Felicia |last5=Meshkat |first5=Shakila |last6=Lui |first6=Leanna M. W. |last7=Fancy |first7=Farhan |last8=Rosenblat |first8=Joshua D. |last9=McIntyre |first9=Roger S. |date=2022-10-15 |title=Active mechanisms of ketamine-assisted psychotherapy: A systematic review |url=https://www.sciencedirect.com/science/article/pii/S0165032722007984 |journal=Journal of Affective Disorders |language=en |volume=315 |pages=105–112 |doi=10.1016/j.jad.2022.07.030 |pmid=35905796 |s2cid=251141313 |issn=0165-0327}}</ref> As demonstrated in animal models, the administration of ketamine propagates signaling pathways surmised to augment neuroplasticity. Key among these are [[MTOR|mammalian target of rapamycin (mTOR)]], [[GSK-3|glycogen synthase kinase-3 (GSK3)]], and [[EEF2K|elongation factor 2 (eEF2) kinase]].<ref name=":0" /> Ketamine has also demonstrated its ability to increase [[Brain-derived neurotrophic factor|brain-derived neurotrophic factor (BDNF)]] levels within the brain in animal studies, which ameliorates the effects of acute and chronic stress.<ref>{{Cite journal |last1=Du |first1=Rui |last2=Han |first2=Ruili |last3=Niu |first3=Kun |last4=Xu |first4=Jiaqiao |last5=Zhao |first5=Zihou |last6=Lu |first6=Guofang |last7=Shang |first7=Yulong |date=2022-03-09 |title=The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis |journal=Frontiers in Psychiatry |volume=13 |pages=813103 |doi=10.3389/fpsyt.2022.813103 |issn=1664-0640 |pmc=8959757 |pmid=35356723|doi-access=free }}</ref> The subsequent increase in both synaptic excitation and neuroplasticity is believed to precipitate the powerful and immediate symptom reduction ketamine elicits for a variety of conditions. It has additionally been theorized that ketamine disrupts the reconsolidation of dysfunctional memories and, through doing so, diminishes the burden of those associated with trauma, anxiety, substance use, and so on.<ref>{{Cite journal |last1=Stein |first1=Murray B. |last2=Simon |first2=Naomi M. |date=2021-02-01 |title=Ketamine for PTSD: Well, Isn't That Special |url=http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.20121677 |journal=American Journal of Psychiatry |language=en |volume=178 |issue=2 |pages=116–118 |doi=10.1176/appi.ajp.2020.20121677 |pmid=33517752 |s2cid=231752701 |issn=0002-953X}}</ref>
There are several hypotheses as to the underlying neural and cognitive mechanisms responsible for the psychiatric effects of ketamine.<ref name=":03" /> Its mechanism of action is as an NMDA receptor antagonist. As such, [[Glutamic acid|glutamate]] modulation is a well-known effect, which is specifically believed to confer increased synaptic excitability. Notably, however, the effects of ketamine are now believed to be larger in scope than previously thought, ultimately leading to greater synaptogenesis and [[neuroplasticity]].<ref>{{Cite journal |last=Joneborg |first=Isak |last2=Lee |first2=Yena |last3=Di Vincenzo |first3=Joshua D. |last4=Ceban |first4=Felicia |last5=Meshkat |first5=Shakila |last6=Lui |first6=Leanna M. W. |last7=Fancy |first7=Farhan |last8=Rosenblat |first8=Joshua D. |last9=McIntyre |first9=Roger S. |date=2022-10-15 |title=Active mechanisms of ketamine-assisted psychotherapy: A systematic review |url=https://www.sciencedirect.com/science/article/pii/S0165032722007984 |journal=Journal of Affective Disorders |language=en |volume=315 |pages=105–112 |doi=10.1016/j.jad.2022.07.030 |issn=0165-0327}}</ref> As demonstrated in animal models, the administration of ketamine propagates signaling pathways surmised to augment neuroplasticity. Key among these are [[MTOR|mammalian target of rapamycin (mTOR)]], [[GSK-3|glycogen synthase kinase-3 (GSK3)]], and [[EEF2K|elongation factor 2 (eEF2) kinase]].<ref name=":03" /> Ketamine has also demonstrated its ability to increase [[Brain-derived neurotrophic factor|brain-derived neurotrophic factor (BDNF)]] levels within the brain in animal studies, which ameliorates the effects of acute and chronic stress.<ref>{{Cite journal |last=Du |first=Rui |last2=Han |first2=Ruili |last3=Niu |first3=Kun |last4=Xu |first4=Jiaqiao |last5=Zhao |first5=Zihou |last6=Lu |first6=Guofang |last7=Shang |first7=Yulong |date=2022 |title=The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis |url=https://www.frontiersin.org/articles/10.3389/fpsyt.2022.813103 |journal=Frontiers in Psychiatry |volume=13 |doi=10.3389/fpsyt.2022.813103 |issn=1664-0640 |pmc=PMC8959757 |pmid=35356723}}</ref> The subsequent increase in both synaptic excitation and neuroplasticity is believed to precipitate the powerful and immediate symptom reduction ketamine elicits for a variety of conditions. It has additionally been theorized that ketamine disrupts the reconsolidation of dysfunctional memories and, through doing so, diminishes the burden of those associated with trauma, anxiety, substance use, and so on.<ref>{{Cite journal |last=Stein |first=Murray B. |last2=Simon |first2=Naomi M. |date=2021-02-01 |title=Ketamine for PTSD: Well, Isn’t That Special |url=http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.20121677 |journal=American Journal of Psychiatry |language=en |volume=178 |issue=2 |pages=116–118 |doi=10.1176/appi.ajp.2020.20121677 |issn=0002-953X}}</ref>


== Treatment-resistant depression ==
== In combination with psychotherapy ==
Given the physiological effects of ketamine, it is hypothesized to be uniquely capable of exceptional efficacy when combined with psychotherapy. The increased neuroplasticity conferred by ketamine is believed to accelerate a patient’s response to psychotherapy and enhance implementation of therapeutic concepts. One example of this may be demonstrated through consideration of [[Cognitive behavioral therapy|cognitive behavioral therapy (CBT)]], a psychotherapy approach that works by targeting cognitive distortions.<ref>{{Cite book |last=Davies |first=Martin |url=https://books.google.com/books?id=e3uMDwAAQBAJ&dq=what+is+cbt&pg=PA423 |title=The Blackwell Companion to Social Work |date=2013-04-01 |publisher=John Wiley & Sons |isbn=978-1-118-45172-4 |language=en}}</ref> By focusing on reversing irrational thought patterns and maladaptive information processing, it ultimately improves emotional regulation. The effects of ketamine are believed to expedite the learning of these frameworks as well as generate greater openness to new ideas.<ref name=":2" /> Several other types of psychotherapy have been used in studies with ketamine, including motivational enhancement therapy (MET),<ref name=":0" /> functional analytic psychotherapy (FAP),<ref name=":0" /> and mindfulness-based relapse prevention (MBRP).<ref name=":2" />


=== Efficacy in treatment ===
⚫
== References ==
The use of ketamine as an antidepressant has mainly been studied for the treatment of [[treatment-resistant depression]](TRD). Single-dose use has been found to have noticeable and rapid anti-depressive effects that tend to last up to a week, accompanied by acute side-effects that resolve spontaneously.<ref>{{Cite journal |last=Corriger |first=Alexandrine |last2=Pickering |first2=Gisèle |date=2019-12-31 |title=Ketamine and depression: a narrative review |url=https://www.tandfonline.com/doi/abs/10.2147/DDDT.S221437 |journal=Drug Design, Development and Therapy |volume=13 |pages=3051–3067 |doi=10.2147/DDDT.S221437 |pmc=PMC6717708 |pmid=31695324}}</ref> It has also been shown to have a moderate-to-large effect in reducing [[suicidality]] in some patients suffering from suicidal ideation<ref>{{Cite journal |last=Nowacka |first=Agata |last2=Borczyk |first2=Malgorzata |date=2019-10 |title=Ketamine applications beyond anesthesia – A literature review |url=https://linkinghub.elsevier.com/retrieve/pii/S0014299919304996 |journal=European Journal of Pharmacology |language=en |volume=860 |pages=172547 |doi=10.1016/j.ejphar.2019.172547}}</ref>, with visible efficacy within two hours of administration. This is in sharp contrast with currently-approved treatment options, whose delayed onset poses an increased risk for suicidality in patients. However, this potency cannot currently be generalised for non-depressed patients experiencing suicidal ideation.
{{Reflist}}


==== Protocol and Administration ====
Repeated sessions of KAP have also been found to be an effective method for facilitating clinically-significant reduction in anxiety and depression, when conducted in private practice settings. Sessions may last up to 3 hours, with provisions for supervised recovery towards the end.<ref name=":23" /> The time-to-relapse after ketamine treatment is typically 2-4 weeks, which is why a repeated dosage paradigm is used to increase KAP’s efficacy on treatment-resistant depression.

The mode of ketamine administration is a crucial consideration in the use of KAP for depression. It employs a dosage escalation strategy<ref name=":23" /> to achieve different levels of dissociative effects, depending on the amount of alteration of consciousness needed for treatment. Lower-dose sublingual administration is recommended for sessions that require active therapist-patient communication, and higher-dose intramuscular administration takes place when an inward focus is needed, with eye coverings and music provided<ref name=":32" />. There is no notable difference in efficacy, however.<ref>{{Cite journal |last=Andrade |first=Chittaranjan |date=2017-08-23 |title=Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? |url=https://www.psychiatrist.com/jcp/depression/ketamine-for-depression-dosing-administration-and-duration/ |journal=The Journal of Clinical Psychiatry |language=English |volume=78 |issue=7 |pages=10106 |doi=10.4088/JCP.17f11738 |issn=0160-6689}}</ref><ref name=":32" /> Guidelines for the provision of psychotherapy are also variably defined, depending on the application, with it being delivered either simultaneously, or following the infusion of ketamine.<ref name=":32" />

=== Legality ===
The use of ketamine for any form of psychiatric treatment is not permitted by the FDA. In 2019, however, it approved the use of esketamine (Spravato) as a nasal spray, in conjunction with an oral antidepressant, for treatment-resistant depression in adults. Potential risks associated with it include dissociation, sedation and abuse. Esketamine cannot be distributed outside of certified clinical settings.<ref name=":0" />

== Limitations and future directions ==
KAP has the potential to show significant efficacy in the treatment of treatment-resistant depression and suicidality, among other mental disorders. But, extensive further research is needed for its effects and mechanisms of action to be properly understood. Currently, the lack of large, replicated clinical trials prevent existing results from being generalisable to the larger population. The current model of KAP also uses repeated administration of ketamine, the long-term side effects of which are not fully known yet. High doses of ketamine could also have potentially toxic effects in patients.<ref>{{Cite journal |last=Short |first=Brooke |last2=Fong |first2=Joanna |last3=Galvez |first3=Veronica |last4=Shelker |first4=William |last5=Loo |first5=Colleen K |date=2018-01 |title=Side-effects associated with ketamine use in depression: a systematic review |url=https://linkinghub.elsevier.com/retrieve/pii/S2215036617302729 |journal=The Lancet Psychiatry |language=en |volume=5 |issue=1 |pages=65–78 |doi=10.1016/S2215-0366(17)30272-9}}</ref> Given that existing studies only have short-term follow-up, the long-term safety of patients who undergo repeated dosing is, therefore, unknown. Future trials should be of larger scale, with repeated ketamine dosing, regular monitoring and follow-up. They should also focus on integrating ketamine with other forms of therapy, including, but not limited to [[motivational enhancement therapy]] (MET)<ref name=":03" />, and [[functional analytic psychotherapy]] (FAP)<ref name=":03" />.

⚫
== References ==
<references />
[[Category:Psychotherapy]]
[[Category:Psychotherapy]]


Revision as of 07:45, 29 March 2023

Part of a series on
Psychology
Basic psychology
Applied psychology
Concepts
Lists

Ketamine-assisted psychotherapy (KAP), is the use of prescribed doses of ketamine, the drug, as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive-compulsive disorders (OCD), and post-traumatic stress disorders (PTSD). It can also be used for those experiencing substance abuse and physical pain. While it is primarily used as a veterinary anaesthetic, ketamine has also been found to have rapid analgesic and hallucinogenic effects[1][2], which has sparked interest in its use as an antidepressant. Despite initial trials of its use in the treatment of mental disorders focussing primarily on its antidepressant effects, newer studies are attempting to harness its psychedelic effects to bring about altered states of consciousness, which will augment the adjunct psychotherapy. Ketamine’s neuroplasticity-promoting effects strengthen the cognitive restructuring that takes place through traditional psychotherapy, thereby leading to long-lasting behavioural change[3][4]. KAP offers promising directions for research on new antidepressant alternatives, but is still not sufficiently defined or evaluated as a treatment combination.

Background

Ketamine is a short-acting, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist[1]. It was discovered by Parke-Davis Labs and Dr. Calvin Lee Stevens in 1962 during research into derivatives of phencyclidine (PCP).[5] It was first used clinically as a veterinary anaesthetic. Given its hallucinogenic properties, interest rapidly rose in the possibility of broader avenues of application, including within the field of psychiatry as a treatment for depression, substance use dependence, and more.[6] The USA Food and Drug Administration (FDA) first approved the use of intranasal esketamine (Spravato)—an enantiomer of ketamine—for the use of ketamine-derived therapy for treatment-resistant depression, in 2019.[7] Ketamine is currently one of the two injected general anaesthetics that the World Health Organisation includes in its Model List of Essential Medicines.

Rationale behind ketamine-assisted psychotherapy

Current antidepressant treatment is heavily limited by its delayed onset of efficacy, with noticeable effects only appearing over a period of months. The Sequenced Treatment Alternatives to Relieve Depression Study (STAR*D) Trial[8] also found that patients had low response rates to alternative compounds after the failure of the first antidepressant.[1][9] Thus, a need for more rapid, yet prolonged, efficacy in treatment has stimulated further research on alternative treatment options.

Research evidence has found that the integrated use of psychotherapy and antidepressant medication to treat mental disorders, enhances the effects of both[1][6][10]. The combination of pharmacotherapy and psychotherapy has historically been efficacious in numerous instances, such as the pairing of psychotherapy with conventional antidepressants for mood and anxiety disorders, with naltrexone for alcohol and opioid dependence, and with bupropion for smoking cessation.[5] Ketamine offers a notable advantage as opposed to currently-approved antidepressants, as it has a rapid onset[11] (2-24 hours post-infusion)[12] of temporally limited, but sustained, antidepressant and analgesic effects (typically lasting 4-7 days).[1] Its dissociative, psychedelic effects could also provide patients with increased neuroplasticity and cognitive flexibility that would enable more effective participation in therapy sessions.[11] Therapy could, in turn, reinforce the effects and improvements facilitated by ketamine to provide longer-lasting treatment[11][13]. Supplementing ketamine use with cognitive behaviour therapy (CBT), in particular, has the potential to help patients reverse their inaccurate beliefs and maladaptive processing of information, that lead to depressive mental states.[14]

Active mechanisms

There are several hypotheses as to the underlying neural and cognitive mechanisms responsible for the psychiatric effects of ketamine.[1] Its mechanism of action is as an NMDA receptor antagonist. As such, glutamate modulation is a well-known effect, which is specifically believed to confer increased synaptic excitability. Notably, however, the effects of ketamine are now believed to be larger in scope than previously thought, ultimately leading to greater synaptogenesis and neuroplasticity.[15] As demonstrated in animal models, the administration of ketamine propagates signaling pathways surmised to augment neuroplasticity. Key among these are mammalian target of rapamycin (mTOR), glycogen synthase kinase-3 (GSK3), and elongation factor 2 (eEF2) kinase.[1] Ketamine has also demonstrated its ability to increase brain-derived neurotrophic factor (BDNF) levels within the brain in animal studies, which ameliorates the effects of acute and chronic stress.[16] The subsequent increase in both synaptic excitation and neuroplasticity is believed to precipitate the powerful and immediate symptom reduction ketamine elicits for a variety of conditions. It has additionally been theorized that ketamine disrupts the reconsolidation of dysfunctional memories and, through doing so, diminishes the burden of those associated with trauma, anxiety, substance use, and so on.[17]

Treatment-resistant depression

Efficacy in treatment

The use of ketamine as an antidepressant has mainly been studied for the treatment of treatment-resistant depression(TRD). Single-dose use has been found to have noticeable and rapid anti-depressive effects that tend to last up to a week, accompanied by acute side-effects that resolve spontaneously.[18] It has also been shown to have a moderate-to-large effect in reducing suicidality in some patients suffering from suicidal ideation[19], with visible efficacy within two hours of administration. This is in sharp contrast with currently-approved treatment options, whose delayed onset poses an increased risk for suicidality in patients. However, this potency cannot currently be generalised for non-depressed patients experiencing suicidal ideation.

Protocol and Administration

Repeated sessions of KAP have also been found to be an effective method for facilitating clinically-significant reduction in anxiety and depression, when conducted in private practice settings. Sessions may last up to 3 hours, with provisions for supervised recovery towards the end.[6] The time-to-relapse after ketamine treatment is typically 2-4 weeks, which is why a repeated dosage paradigm is used to increase KAP’s efficacy on treatment-resistant depression.

The mode of ketamine administration is a crucial consideration in the use of KAP for depression. It employs a dosage escalation strategy[6] to achieve different levels of dissociative effects, depending on the amount of alteration of consciousness needed for treatment. Lower-dose sublingual administration is recommended for sessions that require active therapist-patient communication, and higher-dose intramuscular administration takes place when an inward focus is needed, with eye coverings and music provided[10]. There is no notable difference in efficacy, however.[20][10] Guidelines for the provision of psychotherapy are also variably defined, depending on the application, with it being delivered either simultaneously, or following the infusion of ketamine.[10]

Legality

The use of ketamine for any form of psychiatric treatment is not permitted by the FDA. In 2019, however, it approved the use of esketamine (Spravato) as a nasal spray, in conjunction with an oral antidepressant, for treatment-resistant depression in adults. Potential risks associated with it include dissociation, sedation and abuse. Esketamine cannot be distributed outside of certified clinical settings.[7]

Limitations and future directions

KAP has the potential to show significant efficacy in the treatment of treatment-resistant depression and suicidality, among other mental disorders. But, extensive further research is needed for its effects and mechanisms of action to be properly understood. Currently, the lack of large, replicated clinical trials prevent existing results from being generalisable to the larger population. The current model of KAP also uses repeated administration of ketamine, the long-term side effects of which are not fully known yet. High doses of ketamine could also have potentially toxic effects in patients.[21] Given that existing studies only have short-term follow-up, the long-term safety of patients who undergo repeated dosing is, therefore, unknown. Future trials should be of larger scale, with repeated ketamine dosing, regular monitoring and follow-up. They should also focus on integrating ketamine with other forms of therapy, including, but not limited to motivational enhancement therapy (MET)[1], and functional analytic psychotherapy (FAP)[1].

References

  1. ^ a b c d e f g h i Drozdz, Sandra J; Goel, Akash; McGarr, Matthew W; Katz, Joel; Ritvo, Paul; Mattina, Gabriella F; Bhat, Venkat; Diep, Calvin; Ladha, Karim S (2022-12-31). "Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature". Journal of Pain Research. 15: 1691–1706. doi:10.2147/JPR.S360733. PMC 9207256. PMID 35734507.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  2. ^ Nowacka, Agata; Borczyk, Malgorzata (2019-10-05). "Ketamine applications beyond anesthesia – A literature review". European Journal of Pharmacology. 860: 172547. doi:10.1016/j.ejphar.2019.172547. ISSN 0014-2999.
  3. ^ Krystal, John H. (2007-10-15). "Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy". Biological Psychiatry. 62 (8): 833–834. doi:10.1016/j.biopsych.2007.08.017. ISSN 0006-3223.
  4. ^ Greenway, Kyle T.; Garel, Nicolas; Jerome, Lisa; Feduccia, Allison A. (2020-06-02). "Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments". Expert Review of Clinical Pharmacology. 13 (6): 655–670. doi:10.1080/17512433.2020.1772054. ISSN 1751-2433. PMID 32478631.
  5. ^ a b Mathai, David S.; Mora, Victoria; Garcia-Romeu, Albert (2022). "Toward Synergies of Ketamine and Psychotherapy". Frontiers in Psychology. 13. doi:10.3389/fpsyg.2022.868103. ISSN 1664-1078. PMC 8992793. PMID 35401323.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  6. ^ a b c d Dore, Jennifer; Turnipseed, Brent; Dwyer, Shannon; Turnipseed, Andrea; Andries, Julane; Ascani, German; Monnette, Celeste; Huidekoper, Angela; Strauss, Nicole; Wolfson, Phil (2019-03-15). "Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy". Journal of Psychoactive Drugs. 51 (2): 189–198. doi:10.1080/02791072.2019.1587556. ISSN 0279-1072. PMID 30917760.
  7. ^ a b Research, Center for Drug Evaluation and (2022-02-16). "FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray". FDA.
  8. ^ Sinyor, Mark; Schaffer, Ayal; Levitt, Anthony (2010-03). "The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review". The Canadian Journal of Psychiatry. 55 (3): 126–135. doi:10.1177/070674371005500303. ISSN 0706-7437. {{cite journal}}: Check date values in: |date= (help)
  9. ^ Naughton, Marie; Clarke, Gerard; O′Leary, Olivia F.; Cryan, John F.; Dinan, Timothy G. (2014-03-01). "A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action". Journal of Affective Disorders. 156: 24–35. doi:10.1016/j.jad.2013.11.014. ISSN 0165-0327.
  10. ^ a b c d Walsh, Zach; Mollaahmetoglu, Ozden Merve; Rootman, Joseph; Golsof, Shannon; Keeler, Johanna; Marsh, Beth; Nutt, David J.; Morgan, Celia J. A. (2022-01). "Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review". BJPsych Open. 8 (1): e19. doi:10.1192/bjo.2021.1061. ISSN 2056-4724. {{cite journal}}: Check date values in: |date= (help)
  11. ^ a b c Hasler, Gregor (2020-06). "Toward specific ways to combine ketamine and psychotherapy in treating depression". CNS Spectrums. 25 (3): 445–447. doi:10.1017/S1092852919001007. ISSN 1092-8529. {{cite journal}}: Check date values in: |date= (help)
  12. ^ Singh, Jaskaran B.; Fedgchin, Maggie; Daly, Ella J.; De Boer, Peter; Cooper, Kimberly; Lim, Pilar; Pinter, Christine; Murrough, James W.; Sanacora, Gerard; Shelton, Richard C.; Kurian, Benji; Winokur, Andrew; Fava, Maurizio; Manji, Husseini; Drevets, Wayne C. (2016-08). "A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression". American Journal of Psychiatry. 173 (8): 816–826. doi:10.1176/appi.ajp.2016.16010037. ISSN 0002-953X. {{cite journal}}: Check date values in: |date= (help)
  13. ^ Doblin, Richard E.; Christiansen, Merete; Jerome, Lisa; Burge, Brad (2019-03-15). "The Past and Future of Psychedelic Science: An Introduction to This Issue". Journal of Psychoactive Drugs. 51 (2): 93–97. doi:10.1080/02791072.2019.1606472. ISSN 0279-1072. PMID 31132970.
  14. ^ Joneborg, Isak; Lee, Yena; Di Vincenzo, Joshua D.; Ceban, Felicia; Meshkat, Shakila; Lui, Leanna M. W.; Fancy, Farhan; Rosenblat, Joshua D.; McIntyre, Roger S. (2022-10-15). "Active mechanisms of ketamine-assisted psychotherapy: A systematic review". Journal of Affective Disorders. 315: 105–112. doi:10.1016/j.jad.2022.07.030. ISSN 0165-0327.
  15. ^ Joneborg, Isak; Lee, Yena; Di Vincenzo, Joshua D.; Ceban, Felicia; Meshkat, Shakila; Lui, Leanna M. W.; Fancy, Farhan; Rosenblat, Joshua D.; McIntyre, Roger S. (2022-10-15). "Active mechanisms of ketamine-assisted psychotherapy: A systematic review". Journal of Affective Disorders. 315: 105–112. doi:10.1016/j.jad.2022.07.030. ISSN 0165-0327.
  16. ^ Du, Rui; Han, Ruili; Niu, Kun; Xu, Jiaqiao; Zhao, Zihou; Lu, Guofang; Shang, Yulong (2022). "The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis". Frontiers in Psychiatry. 13. doi:10.3389/fpsyt.2022.813103. ISSN 1664-0640. PMC 8959757. PMID 35356723.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  17. ^ Stein, Murray B.; Simon, Naomi M. (2021-02-01). "Ketamine for PTSD: Well, Isn't That Special". American Journal of Psychiatry. 178 (2): 116–118. doi:10.1176/appi.ajp.2020.20121677. ISSN 0002-953X.
  18. ^ Corriger, Alexandrine; Pickering, Gisèle (2019-12-31). "Ketamine and depression: a narrative review". Drug Design, Development and Therapy. 13: 3051–3067. doi:10.2147/DDDT.S221437. PMC 6717708. PMID 31695324.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  19. ^ Nowacka, Agata; Borczyk, Malgorzata (2019-10). "Ketamine applications beyond anesthesia – A literature review". European Journal of Pharmacology. 860: 172547. doi:10.1016/j.ejphar.2019.172547. {{cite journal}}: Check date values in: |date= (help)
  20. ^ Andrade, Chittaranjan (2017-08-23). "Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?". The Journal of Clinical Psychiatry. 78 (7): 10106. doi:10.4088/JCP.17f11738. ISSN 0160-6689.
  21. ^ Short, Brooke; Fong, Joanna; Galvez, Veronica; Shelker, William; Loo, Colleen K (2018-01). "Side-effects associated with ketamine use in depression: a systematic review". The Lancet Psychiatry. 5 (1): 65–78. doi:10.1016/S2215-0366(17)30272-9. {{cite journal}}: Check date values in: |date= (help)
Stub icon

This medical treatment–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ketamine-assisted_psychotherapy&oldid=1147169446"